Neurobehavioral Manifestations clinical trials
The registry lists 130 studies for Neurobehavioral Manifestations across more than 10 countries. 27 are recruiting or about to start. 22 of them are mainly about Neurobehavioral Manifestations (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 46 narrower conditions too, such as Delirium: 6,328 studies, 1,544 open.
Get an email when these change. Save the Neurobehavioral Manifestations studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
VA Office of Research and Development (5) · AO GENERIUM (3) · UMC Utrecht (3) · Connecta Therapeutics, S.L. (3) · Vanderbilt University Medical Center (3) · Radboud University Medical Center (2) · Massachusetts General Hospital (2) · Beth Israel Deaconess Medical Center (2)
What is being tested here
Drugs under test in Neurobehavioral Manifestations studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Guanfacine | 1 | 0 | 2 |
| Baricitinib | 1 | 0 | 1 |
| Sertraline | 1 | 0 | 1 |
| Dexmedetomidine | 1 | 0 | 1 |
| Modafinil | 0 | 0 | 2 |
| Metformin | 0 | 1 | 2 |
| Ketamine | 0 | 0 | 2 |
| Ethanol | 0 | 0 | 2 |
| Minocycline | 0 | 1 | 2 |
| Escitalopram | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 10
- Dec 2026Modafinil and Cognitive Function in POTS · Vanderbilt University Medical Center
- Dec 2026Evaluation of Impact of AI Assistance on Workload Associated w Preparation of Rare Tumor Case Repts · UNC Lineberger Comprehensive Cancer Center
- Dec 2026Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease · The University of Texas Health Science Center at San Antonio
- Mar 2027Cognitive Rehabilitation for Victims of War and Related Traumas With Traumatic Brain Injury and Cognitive Impairment · Massachusetts General Hospital
- Mar 2027Problem-Solving Training for Concussion · VA Office of Research and Development
- Apr 2027PrimeCog: Primary Care Cognitive Testing · Region Östergötland
- May 2027Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome · Connecta Therapeutics, S.L.
- Jul 2027Rett Syndrome Registry · International Rett Syndrome Foundation
- Sep 2027Improving Measurement and Treatment of Post-stroke Neglect · VA Office of Research and Development
- Oct 2027JAK Signaling in Depression and Cognition in Male Football Players · Emory University
Who these studies take
Of the 21 Neurobehavioral Manifestations studies recruiting now, 6 (29%) set no upper age limit and 11 (52%) stop at 75 or younger. 5 (24%) take children under 18. 0 (0%) are for women only and 2 (10%) for men only; 4 (19%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (19%) | 4 (19%) |
| 18 | 13 (62%) | 14 (67%) |
| 30 | 14 (67%) | 16 (76%) |
| 40 | 14 (67%) | 16 (76%) |
| 50 | 14 (67%) | 15 (71%) |
| 65 | 13 (62%) | 13 (62%) |
| 75 | 10 (48%) | 10 (48%) |
| 85 | 10 (48%) | 10 (48%) |
Across all 130 studies, recruiting or not: 54% stop at 75 or younger and 49% at 65; 22% take children; 3% are for women only and 5% for men only; 30% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Neurobehavioral Manifestations studies take
Of 36 interventional studies with no phase under Neurobehavioral Manifestations, half reached primary completion within 24 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Interventional, no phase | 24 mo15–31 · 36 studies | — | 24 mo15–31 · 36 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 130. Browse all 130 → or search them.
- Using Non-invasive Brain Stimulation to Treat Word Finding Difficulty in Chronic Traumatic Brain InjuryRecruitingNCT06848140Not applicable1 country
- Cognitive Enhancement in Recurrent Depression (The COG-D-R Study)Not yet recruitingNCT07527273Not applicable1 country
- Improving Measurement and Treatment of Post-stroke NeglectRecruitingNCT03317860Not applicable1 country
- The Neurodevelopmental and Behavioral Phenotyping Screening ProtocolRecruitingNCT002716221 country
- JAK Signaling in Depression and Cognition in Male Football PlayersRecruitingNCT07608796Phase 21 country
- Evaluation of Impact of AI Assistance on Workload Associated w Preparation of Rare Tumor Case ReptsNot yet recruitingNCT06026098Not applicable1 country
- NeuroFinance Human Stress Trial During Financial and Informational VolatilityEnrolling by invitationNCT076225891 country
- Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X SyndromeRecruitingNCT07654114Phase 21 country
- Cognitive Rehabilitation for Victims of War and Related Traumas With Traumatic Brain Injury and Cognitive ImpairmentRecruitingNCT06839079Not applicable1 country
- Cranberry Polyphenols and Stress Resilience During Multitasking in Healthy AdultsRecruitingNCT07453537Not applicable1 country
- Rett Syndrome RegistryRecruitingNCT054323491 country
- Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium BenzoateRecruitingNCT06340789Phase 21 country
- ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in DepressionRecruitingNCT06408246Phase 21 country
- Personalized Brain Stimulation to Treat Chronic Concussive SymptomsRecruitingNCT06073886Phase 21 country
- Advancing Alzheimer's Care: Home-based tDCS for Affective SymptomsRecruitingNCT06801639Not applicable1 country
- Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's DiseaseRecruitingNCT06843252Not applicable1 country
- PQQ for Cognitive and Negative SymptomsNot yet recruitingNCT07393464Not applicable
- Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery PatientsRecruitingNCT04289142Phase 41 country
- Problem-Solving Training for ConcussionRecruitingNCT05837676Not applicable1 country
- NapBiome: Targeting Gut Microbiota and Sleep Rhythm to Improve Developmental and Behavioral Outcomes in Early ChildhoodNot yet recruitingNCT06396689Not applicable1 country
- Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 MonthsRecruitingNCT066620451 country
- Study the Efficacy and Safety of the INtegral Cognitive REMediation Program (INCREM) for DepressionRecruitingNCT06590025Phase 31 country
- Occupational Therapy Intervention on the Prevention of Delirium and Occupational Performance Status in Elderly PatientsNot yet recruitingNCT06479031Not applicable
- PrimeCog: Primary Care Cognitive TestingRecruitingNCT063465351 country
- Food Allergy in the BrainRecruitingNCT058394051 country
- Cognition and QoL After Thyroid SurgeryRecruitingNCT050881871 country
- SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of AutismRecruitingNCT032223752 countries
- Acute Cognitive Changes During Atrial Fibrillation Episodes (AFCOG)CompletedNCT040335101 country
- Investigation of the Benefits of Electrical Non-invasive Stimulation on Cognitive Symptoms in Parkinson's DiseaseActive, not recruitingNCT05808504Not applicable1 country
- Effect of Extended Cannabis Abstinence on PTSD SymptomsCompletedNCT05162651Not applicable1 country
- Cognitive Enhancement in Depression (The COG-D Study)CompletedNCT05400512Not applicable1 country
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type IIActive, not recruitingNCT05208281Phase 2/31 country
- Can Cranberry Juice Enhance the Cognition Accuracy and Alleviate Negative Mental Consequences During Multitasking?SuspendedNCT06066619Not applicable1 country
- Berberine Improving Cognitive Impairments in SchizophreniaCompletedNCT07359209Not applicable1 country
- Neurobiological Mechanisms of Pathological Rumination and Effects of AripiprazoleActive, not recruitingNCT06937476Not applicable1 country
- A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett SyndromeActive, not recruitingNCT05898620Phase 33 countries
- Cognitive Rehabilitation of Blast Traumatic Brain Injury (TBI)CompletedNCT01138020Not applicable1 country
- Modafinil and Cognitive Function in POTSActive, not recruitingNCT01988883Early Phase 11 country
- A Trial of Metformin in Individuals With Fragile X Syndrome (Met)CompletedNCT03862950Phase 21 country
- NiPPeR Randomised Trial - Child Follow Up StudyCompletedNCT05934422Not applicable3 countries
- Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral IschemiaCompletedNCT06834490Phase 32 countries
- Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19CompletedNCT04809974Phase 41 country
- Integral Cognitive Remediation for DepressionCompletedNCT07014683Not applicable1 country
- Neural Biomarkers in Fragile X SyndromeCompletedNCT069570541 country
- A Two Year Longitudinal Clinical Study of Neurocognitive and Psychiatric Symptoms in Post COVID-19 PatientsActive, not recruitingNCT062980061 country
- CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food InteractionCompletedNCT06480968Phase 11 country
- A Trial of Metformin in Individuals With Fragile X SyndromeCompletedNCT03479476Phase 2/32 countries
- Dopaminergic Therapy for Frontotemporal Dementia PatientsCompletedNCT04937452Phase 21 country
- Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi SyndromeCompletedNCT05657860Phase 41 country
- Chronic Neck Pain and Cognitive FunctionCompletedNCT065040041 country